BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18720362)

  • 1. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM; Figlin RA; Hutson TE; Michaelson MD; Kim ST; Baum CM; Kattan MW
    Cancer; 2008 Oct; 113(7):1552-8. PubMed ID: 18720362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.
    Patil S; Figlin RA; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Motzer RJ
    Ann Oncol; 2011 Feb; 22(2):295-300. PubMed ID: 20657034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
    Claret L; Zheng J; Mercier F; Chanu P; Chen Y; Rosbrook B; Yazdi P; Milligan PA; Bruno R
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):605-10. PubMed ID: 27468922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.
    Karakiewicz PI; Sun M; Bellmunt J; Sneller V; Escudier B
    Eur Urol; 2011 Jul; 60(1):48-56. PubMed ID: 21190790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
    Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib.
    Kattan MW; Sternberg CN; Mehmud F; Bhatt K; McCann L; Motzer RJ
    Oncology; 2015; 89(4):235-41. PubMed ID: 26088013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
    Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
    Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
    Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib efficacy against advanced renal cell carcinoma.
    Motzer RJ; Michaelson MD; Rosenberg J; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Wilding G
    J Urol; 2007 Nov; 178(5):1883-7. PubMed ID: 17868732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
    Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
    Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib rechallenge in metastatic renal cell carcinoma patients.
    Zama IN; Hutson TE; Elson P; Cleary JM; Choueiri TK; Heng DY; Ramaiya N; Michaelson MD; Garcia JA; Knox JJ; Escudier B; Rini BI
    Cancer; 2010 Dec; 116(23):5400-6. PubMed ID: 21105118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience.
    Abd Ghafar NK; Alip A; Ong TA; Yap NY; Saad M
    J Cancer Res Ther; 2018; 14(6):1303-1311. PubMed ID: 30488848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.
    Klatte T; Remzi M; Zigeuner RE; Mannweiler S; Said JW; Kabbinavar FF; Haitel A; Waldert M; de Martino M; Marberger M; Belldegrun AS; Pantuck AJ
    J Urol; 2010 Jul; 184(1):53-8. PubMed ID: 20478577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
    Lim ZD; Mahajan A; Weinberg J; Tannir NM
    Am J Clin Oncol; 2013 Jun; 36(3):258-60. PubMed ID: 22441343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
    Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
    Okamura Y; Hinata N; Terakawa T; Furukawa J; Harada K; Nakano Y; Nakamura I; Inoue T; Ogawa T; Fujisawa M
    Int J Clin Oncol; 2019 Jun; 24(6):698-705. PubMed ID: 30798395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.